LUNG CANCER SURGERY MARKET ANALYSIS

Market News

Recent Developments

New product launches

• In May 2022, Olympus Corporation, manufacturer of optical and digital precision technology, launched the BF-UC190F endobronchial ultrasound (EBUS) bronchoscope. The BF-UC190F is a new generation of EBUS bronchoscope that offers improved image quality and navigation capabilities. It is designed to help surgeons better visualize and biopsy lung cancer lesions.
• In February 2022, Intuitive Surgical Inc., a company which develops, manufactures, and markets products that enable physicians and healthcare providers, acquired Orpheus Medical. Orpheus Medical is a developer of robotically-assisted lung biopsy systems. The acquisition of Orpheus Medical will give Intuitive Surgical a new platform for developing robotically-assisted lung cancer surgery systems.
• In December 2020, Medtronic, a medical device company, announced the launch of Tri-Staple EEA Circular Stapler in India. The new Tri-Staple Technology comprises a sloped cartridge face that delivers less stress on tissue. It also offers consistent performance over a broad range of tissue thicknesses and allows for greater perfusion into the staple line. 

Acquisition and partnerships

• In February 2023, Intuitive Surgical Inc., a company which develops, manufactures, and markets products that enable physicians and healthcare providers, acquired Auris Health Inc., a medical device company, Auris Health is a developer of robotically-assisted bronchoscopy systems. The acquisition of Auris Health will give Intuitive Surgical a new platform for developing robotically-assisted lung cancer surgery systems.
• In December 2022, Clinithink, a technology company, announced partnership with AstraZeneca, a biopharmaceutical company, to detect early stage lung cancer
• In March 2021, Agilent Technologies Inc., a provider of instruments, reagents, software, services, and consumables, announced it had entered into a definitive agreement to acquire Resolution Bioscience Inc., a company focused on the development and commercialization of next-generation sequencing (NGS)-based precision oncology solutions. The acquisition complements and expands Agilent Technologies Inc’s., capabilities in NGS-based cancer diagnostics and provides the company with innovative technology to further serve the needs of the fast-growing precision medicine market.